Alloutcoach Tim

The 2025 Medical Innovation Olympics featured one of the most memorable and personal interviews with Amber Salzman, CEO at Epicrispr Biotechnologies, an extraordinary leader with unparalleled sense of purpose, urgency, PhD in mathematics and illustrious track record of success as a pharmaceutical industry executive with over 30 years of experience that included growing revenue, shareholder value, and accelerating innovative treatments. She began her career leading R & D at GSK with a clinical pipeline responsibility for $1.25 billion, prior to serving as CEO at Cardiokine, CEO at Avalanche, co-founder of Annapurna, SAS, CEO of Adverum, Ohana Biosciences. She currently serves on the Osler Diagnostics (UK) and AviadoBio (UK) Boards. In addition to advocating for patients living with rare diseases, Dr. Salzman leads the Stop ALD Foundation, a non-profit medical research foundation focused on developing.In this interview Amber speaks about her personal and family's struggle with neurodegenerative rare disease